Efficacité des Vaccins contre le Papillomavirus Humain

                                     

                                          

En Bref 
La vaccination anti-HPV a été introduite en France en 2007. Elle intervient en complément du dépistage du cancer du col de l'utérus à partir de 25 ans. En décembre 2019, la HAS recommande la vaccination contre les papillomavirus humains (avec le GARDASIL 9) à tous les adolescents, filles et garçons de 11 à 14 ans révolus.  
L’efficacité de la vaccination sur l'incidence du cancer du col de l'utérus ne pouvant être prouvée que plusieurs décennies après l'introduction de la vaccination, des indicateurs intermédiaires sont utilisés pour évaluer son efficacité à court et moyen terme. 
Trois vaccins anti-HPV existent, dont deux sont actuellement disponibles en France (vaccin bivalent et nonavalent). Les vaccins bivalent (HPV 16 et 18), quadrivalent (HPV 6, 11, 16 et 18) et nonavalent (HPV 6, 11, 16, 18, 31, 33, 45, 52, 58) sont efficaces à environ 95% contre les lésions précancéreuses liées aux HPV 16 et 18 (CIN2+), chez les femmes non antérieurement exposées aux HPV. Chez les patients ayant déjà eu des rapports sexuels quelconque, la vaccination réduit également la prévalence du portage des HPV. Les vaccins quadrivalent et nonavalent offrent une protection complémentaire contre les condylomes liés à HPV 6 et 11. Il existe également une diminution des infections buccales, oropharyngées, vulvaires et anales. Les premières données d'efficacité en situation réelle dans la population semblent confirmer les données des essais cliniques, avec également un "effet de troupeau" induit par la vaccination. Cependant, l'efficacité à long terme et l'impact sur l'incidence du cancer du col de l'utérus sont encore incertains et doivent être prouvés

                   

cliquez

                                                  

Articles reliés : infections à Papillomavirus, composition du vaccin HPV, effets secondaires généraux, barrières religieuses, syndrome de Guillain-Barré

                   

                    

Sources                              

Revues systématiques et méta-analyses

  • Miksis S. A review of the evidence comparing the human papillomavirus vaccine versus condoms in the prevention of human papillomavirus infections. J Obstet Gynecol Neonatal Nurs. Juin 2008;37(3):329 37. (Prisma ●○○○ ; Amstar ●○○)

  • Garland SM, Kjaer SK, Muñoz N, Block SL, Brown DR, DiNubile MJ, et al. Impact and Effectiveness of the Quadrivalent Human Papillomavirus Vaccine: A Systematic Review of 10 Years of Real-world Experience. Clin Infect Dis. 15 août 2016;63(4):519 27. (Prisma ●●○○ ; Amstar ●○○)

  • Drolet M, Bénard É, Boily M-C, Ali H, Baandrup L, Bauer H, et al. Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis. Lancet Infect Dis. Mai 2015;15(5):565 80. (Prisma ●●●○ ; Amstar ●●●)

  • Steben M, Tan Thompson M, Rodier C, Mallette N, Racovitan V, DeAngelis F, et al. A Review of the Impact and Effectiveness of the Quadrivalent Human Papillomavirus Vaccine: 10 Years of Clinical Experience in Canada. J Obstet Gynaecol Can. 16 oct 2018 (Prisma ●●○○ ; Amstar ●○○)

  • Nielsen KJ, Jakobsen KK, Jensen JS, Grønhøj C, Von Buchwald C. The Effect of Prophylactic HPV Vaccines on Oral and Oropharyngeal HPV Infection-A Systematic Review. Viruses. 2021 Jul 11;13(7):1339. (Prisma ●●○○  ; Amstar ●●○)

  • Di Mario S, Basevi V, Lopalco PL, Balduzzi S, D’Amico R, Magrini N. Are the Two Human Papillomavirus Vaccines Really Similar? A Systematic Review of Available Evidence: Efficacy of the Two Vaccines against HPV. J Immunol Res. 2015;2015:435141. (Prisma ●●●○ ; Amstar ●●○)

  • Malagón T, Drolet M, Boily M-C, Franco EL, Jit M, Brisson J, et al. Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis. Lancet Infect Dis. Oct 2012;12(10):781 9. (Prisma ●●●○ ; Amstar ●●○)

  • Lu B, Kumar A, Castellsagué X, Giuliano AR. Efficacy and safety of prophylactic vaccines against cervical HPV infection and diseases among women: a systematic review & meta-analysis. BMC Infect Dis. 12 janv 2011;11:13. (Prisma ●●●○ ; Amstar ●●●)

  • Haghshenas MR, Mousavi T, Kheradmand M, Afshari M, Moosazadeh M. Efficacy of Human Papillomavirus L1 Protein Vaccines (Cervarix and Gardasil) in Reducing the Risk of Cervical Intraepithelial Neoplasia: A Meta-analysis. Int J Prev Med. 2017;8:44. (Prisma ●●●○ ; Amstar ●●●)

  • Medeiros LR, Rosa DD, da Rosa MI, Bozzetti MC, Zanini RR. Efficacy of human papillomavirus vaccines: a systematic quantitative review. Int J Gynecol Cancer. Oct 2009;19(7):1166 76. (Prisma ●●●○ ; Amstar ●●○)

  • Signorelli C, Odone A, Ciorba V, Cella P, Audisio RA, Lombardi A, et al. Human papillomavirus 9-valent vaccine for cancer prevention: a systematic review of the available evidence. Epidemiol Infect. 2017;145(10):1962 82. (Prisma ●●●○ ; Amstar ●●○)

  • Brisson M, Bénard É, Drolet M, Bogaards JA, Baussano I, Vänskä S, et al. Population-level impact, herd immunity, and elimination after human papillomavirus vaccination: a systematic review and meta-analysis of predictions from transmission-dynamic models. Lancet Public Health. nov 2016;1(1):e8 17. (Prisma ●●●○ ; Amstar ●●○)

  • Rambout L, Hopkins L, Hutton B, Fergusson D. Prophylactic vaccination against human papillomavirus infection and disease in women: a systematic review of randomized controlled trials. CMAJ. 28 août 2007;177(5):469 79. (Prisma ●●●○ ; Amstar ●●●)

  • Miltz A, Price H, Shahmanesh M, Copas A, Gilson R. Systematic review and meta-analysis of L1-VLP-based human papillomavirus vaccine efficacy against anogenital pre-cancer in women with evidence of prior HPV exposure. PLoS ONE. 2014;9(3):e90348. (Prisma ●●●○ ; Amstar ●●○)

  • Deleré Y, Wichmann O, Klug SJ, van der Sande M, Terhardt M, Zepp F, et al. The efficacy and duration of vaccine protection against human papillomavirus: a systematic review and meta-analysis. Dtsch Arztebl Int. 1 sept 2014;111(35 36):584 91. (Prisma ●●●○ ; Amstar ●●●)

  • Brun J-L. [Human papillomavirus vaccines]. J Gynecol Obstet Biol Reprod (Paris). févr 2008;37 Suppl 1:S155-166. (Prisma ●○○○ ; Amstar ●○○)

  • Arbyn M, Xu L, Simoens C, Martin‐Hirsch PP. Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors. Cochrane Database of Systematic Reviews [Internet]. 2018 [cité 1 nov 2018];(5). (Prisma ●●●● ; Amstar ●●●)

  • Yang DY, Bracken K. Update on the new 9-valent vaccine for human papillomavirus prevention. Can Fam Physician. mai 2016;62(5):399‑402. (Prisma ●○○○ ; Amstar ●○○)

  • Aldakak L, Huber VM, Rühli F, Bender N. Sex difference in the immunogenicity of the quadrivalent Human Papilloma Virus vaccine: Systematic review and meta-analysis. Vaccine. 19 mars 2021;39(12):1680‑6.  (Prisma ●●●○; Amstar ●●○)

  • Zhang J, Qin Z, Lou C, Huang J, Xiong Y. The efficacy of vaccination to prevent human papilloma viruses infection at anal and oral: a systematic review and meta-analysis. Public Health. 2021 Jul;196:165-171  (Prisma ●●●○ ; Amstar ●●●)

  • Villa A, Patton LL, Giuliano AR, Estrich CG, Pahlke SC, O'Brien KK, Lipman RD, Araujo MWB. Summary of the evidence on the safety, efficacy, and effectiveness of human papillomavirus vaccines: Umbrella review of systematic reviews. J Am Dent Assoc. 2020 Apr;151(4):245-254.e24. (Prisma ●●○○ ; Amstar ●●○ )

  • Jørgensen L, Gøtzsche PC, Jefferson T. Benefits and harms of the human papillomavirus (HPV) vaccines: systematic review with meta-analyses of trial data from clinical study reports. Syst Rev. 2020 Feb 28;9(1):43. (Prisma ●●●○ ; Amstar ●●○)

  • Bergman H, Buckley BS, Villanueva G, Petkovic J, Garritty C, Lutje V, Riveros-Balta AX, Low N, Henschke N. Comparison of different human papillomavirus (HPV) vaccine types and dose schedules for prevention of HPV-related disease in females and males. Cochrane Database Syst Rev. 2019 Nov 22;2019(11):CD013479. (Prisma ●●●● ; Amstar ●●●)

  • Xu L, Selk A, Garland SM, Bogliatto F, Kyrgiou M, Weyers S, et al. Prophylactic vaccination against human papillomaviruses to prevent vulval and vaginal cancer and their precursors. Expert Rev Vaccines. nov 2019;18(11):1157‑66.  (Prisma ●●○○ ; Amstar ●●○)

  • Drolet M, Bénard É, Pérez N, Brisson M. Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis. Lancet. 10 août 2019;394(10197):497‑509. (Prisma ●●●○ ; Amstar ●●○)

  • García-Perdomo HA, Osorio JC, Fernandez A, Zapata-Copete JA, Castillo A. The effectiveness of vaccination to prevent the papillomavirus infection: a systematic review and meta-analysis. Epidemiol Infect. 20 mars 2019;147:e156. (Prisma ●●●○; Amstar ●●○)

  • Markowitz LE, Drolet M, Perez N, Jit M, Brisson M. Human papillomavirus vaccine effectiveness by number of doses: Systematic review of data from national immunization programs. Vaccine. 2018 Aug 6;36(32 Pt A):4806-4815. (Prisma ●●○○ ; Amstar ●○○)

  • Harder T, Wichmann O, Klug SJ, van der Sande MAB, Wiese-Posselt M. Efficacy, effectiveness and safety of vaccination against human papillomavirus in males: a systematic review. BMC Med. 18 juill 2018;16:110. (Prisma ●●●○ ; Amstar ●●●)

  • Lukács A, Máté Z, Farkas N, Mikó A, Tenk J, Hegyi P, et al. The quadrivalent HPV vaccine is protective against genital warts: a meta-analysis. BMC Public Health. 28 mai 2020;20:691. (Prisma ●●●● ; Amstar ●●●)

  • Brown DR, Joura EA, Yen GP, Kothari S, Luxembourg A, Saah A, et al. Systematic literature review of cross-protective effect of HPV vaccines based on data from randomized clinical trials and real-world evidence. Vaccine. 15 avr 2021;39(16):2224‑36. (Prisma ●●○○ ; Amstar ●●○) 

  • Stanley M, Joura E, Yen GP, Kothari S, Luxembourg A, Saah A, Walia A, Perez G, Khoury H, Badgley D, Brown DR. Systematic literature review of neutralizing antibody immune responses to non-vaccine targeted high-risk HPV types induced by the bivalent and the quadrivalent vaccines. Vaccine. 2021 Apr 15;39(16):2214-2223. (Prisma ●●○○ ; Amstar ●●○)

 

Littérature grise

Affichages : 3505